Evidence map›Paper›PMID 41560804›Full record

ArticleMaterials today. Bio2026

Tissue-engineered cardiac patches enriched with IGF1 modified mRNA alleviate myocardial infarction by enhancing cell survival and angiogenesis.

Bingqian Yan, Xuefeng Ai, Huijing Wang, Yao Tan, Yiqi Gong, Li Yang, Ying Chen, Tingting Lu, Minglu Liu, Runjiao Luo and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Bingqian YanInstitute of Pediatric Translational Medicine, Shanghai Institute of Pediatric Congenital Heart Disease, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China.
Xuefeng AiDepartment of Pediatric Cardiothoracic Surgery, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China.
Huijing WangInstitute of Pediatric Translational Medicine, Shanghai Institute of Pediatric Congenital Heart Disease, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China.
Yao TanInstitute of Pediatric Translational Medicine, Shanghai Institute of Pediatric Congenital Heart Disease, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China.
Yiqi GongDepartment of Pediatric Cardiothoracic Surgery, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China.
Li YangDepartment of Anesthesiology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Ying ChenInstitute of Pediatric Translational Medicine, Shanghai Institute of Pediatric Congenital Heart Disease, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China.
Tingting LuInstitute of Pediatric Translational Medicine, Shanghai Institute of Pediatric Congenital Heart Disease, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China.
Minglu LiuDepartment of Pediatric Cardiothoracic Surgery, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China.
Runjiao LuoDepartment of Pediatric Cardiothoracic Surgery, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China.
Kaixiang LiDepartment of Pediatric Cardiothoracic Surgery, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China.
Xin TangInstitute of Pediatric Translational Medicine, Shanghai Institute of Pediatric Congenital Heart Disease, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China.
Wei WangDepartment of Pediatric Cardiothoracic Surgery, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China.
Wei FuInstitute of Pediatric Translational Medicine, Shanghai Institute of Pediatric Congenital Heart Disease, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tissue-engineered cardiac patches (TECPs), which combine cells with biomaterial scaffolds, hold great promise for myocardial repair and regeneration. However, their broader application remains limited by the low survival rate of transplanted cells. To boost the therapeutic efficacy of cardiac patches, genetic engineering and localized delivery of bioactive factors are essential for optimizing cellular function in vivo. In this study, nanofibrous membranes composed of polycaprolactone-co-l-lactide (PLCL) and gelatin at various ratios were fabricated using electrospinning technology. Among these, membranes containing 30 % gelatin displayed optimal properties, promoting the adhesion, survival, proliferation, and cardiomyocyte differentiation of induced pluripotent stem cell-derived cardiac progenitor cells (iPSC-CPCs). Following this, TECPs were constructed in vitro and transfected with modified mRNA (modRNA) encoding insulin-like growth factor 1 (IGF1). Further evaluations revealed that IGF1 modified mRNA (modIGF1)-enriched TECPs significantly reduced infarct size, enhanced the survival and proliferation of transplanted cells, promoted vascularization and facilitated cardiac functional recovery. The integration of modRNA technology with myocardial patches facilitates the controlled release of therapeutic proteins, thereby preserving cellular function and offering a promising approach to advancing cardiac tissue engineering.

Indexed as

Cardiac regenerationInduced pluripotent stem cellsInsulin-like growth factor 1Modified mRNAMyocardial infarctionTissue-engineered cardiac patch

Identifiers

PMID41560804
PMCPMC12813182

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.